Rep. Lisa C. McClain Purchases Shares of GSK PLC Sponsored ADR (NYSE:GSK)

Key Points

• Rep. Lisa C. McClain (R-Michigan) purchased shares of GSK PLC for between $1,001 and $15,000 on August 4th, 2025, as disclosed in a filing.
• GSK's stock is currently down 0.6% and has reported better-than-expected quarterly earnings, with earnings per share at $1.23, surpassing the estimate of $1.12.
• The company recently cut its dividend to $0.4206 per share, which results in an annual yield of 4.2% and a payout ratio of 77.78%.

Representative Lisa C. McClain (R-Michigan) recently bought shares of GSK PLC Sponsored ADR NYSE: GSK. In a filing disclosed on September 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in GSK stock on August 4th. The trade occurred in the Representative's "CHARLES SCHWAB BROKERAGE ACCOUNT 924" account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $50,001 - $100,000 in shares of Taiwan Semiconductor Manufacturing NYSE: TSM on 8/28/2025.
• Purchased $1,001 - $15,000 in shares of ACI Worldwide NASDAQ: ACIW on 8/19/2025.
• Purchased $1,001 - $15,000 in shares of HCA Healthcare NYSE: HCA on 8/19/2025.
• Sold $1,001 - $15,000 in shares of Amedisys NASDAQ: AMED on 8/18/2025.
• Purchased $1,001 - $15,000 in shares of Kite Realty Group Trust NYSE: KRG on 8/13/2025.
• Sold $1,001 - $15,000 in shares of ServiceNow NYSE: NOW on 8/13/2025.
• Purchased $1,001 - $15,000 in shares of JD.com NASDAQ: JD on 8/13/2025.
• Sold $1,001 - $15,000 in shares of Trade Desk NASDAQ: TTD on 8/13/2025.
• Sold $1,001 - $15,000 in shares of US Foods NYSE: USFD on 8/13/2025.
• Purchased $1,001 - $15,000 in shares of Agree Realty NYSE: ADC on 8/13/2025.

GSK Price Performance

Shares of GSK stock traded up $0.33 during trading on Friday, reaching $40.63. 3,691,363 shares of the company's stock were exchanged, compared to its average volume of 3,611,408. The company has a debt-to-equity ratio of 1.07, a quick ratio of 0.57 and a current ratio of 0.87. GSK PLC Sponsored ADR has a 1-year low of $31.72 and a 1-year high of $42.63. The company has a market cap of $82.75 billion, a P/E ratio of 18.81, a PEG ratio of 2.01 and a beta of 0.53. The firm's 50-day moving average price is $38.90 and its 200 day moving average price is $38.55.

GSK (NYSE:GSK - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 EPS for the quarter, topping analysts' consensus estimates of $1.12 by $0.11. GSK had a return on equity of 49.22% and a net margin of 10.81%.The company had revenue of $10.64 billion during the quarter, compared to analysts' expectations of $7.92 billion. During the same quarter in the previous year, the firm earned $0.43 EPS. GSK's revenue was up 1.3% on a year-over-year basis. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. As a group, research analysts anticipate that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.

GSK Cuts Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 9th. Stockholders of record on Friday, August 15th will be issued a dividend of $0.4206 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 4.1%. GSK's payout ratio is 77.78%.

Institutional Investors Weigh In On GSK

Institutional investors have recently made changes to their positions in the stock. Brighton Jones LLC bought a new stake in shares of GSK during the 4th quarter valued at about $528,000. Focus Partners Wealth raised its stake in GSK by 16.9% during the 4th quarter. Focus Partners Wealth now owns 40,931 shares of the pharmaceutical company's stock worth $1,497,000 after buying an additional 5,912 shares during the period. Pathstone Holdings LLC raised its stake in GSK by 4.1% during the 4th quarter. Pathstone Holdings LLC now owns 256,715 shares of the pharmaceutical company's stock worth $8,686,000 after buying an additional 10,101 shares during the period. Quantinno Capital Management LP raised its stake in GSK by 7.0% during the 4th quarter. Quantinno Capital Management LP now owns 106,753 shares of the pharmaceutical company's stock worth $3,610,000 after buying an additional 6,948 shares during the period. Finally, Sphera Funds Management LTD. raised its stake in GSK by 30.0% during the 4th quarter. Sphera Funds Management LTD. now owns 130,000 shares of the pharmaceutical company's stock worth $4,397,000 after buying an additional 30,000 shares during the period. Institutional investors own 15.74% of the company's stock.

Analyst Ratings Changes

A number of brokerages have issued reports on GSK. Berenberg Bank reaffirmed a "hold" rating on shares of GSK in a report on Tuesday, June 3rd. Wall Street Zen raised GSK from a "buy" rating to a "strong-buy" rating in a report on Friday, September 5th. Six equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Reduce" and a consensus target price of $37.38.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan's 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027. McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan's 9th Congressional District. She declared candidacy for the 2026 election. Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor's degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.